Generic filters
Filter by content type
Taxonomy terms

VYGR – Voyager Therapeutics Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 7.4

Low: 3

High: 10

Total Analysts: 8

Company Profile

Voyager Therapeutics, Inc. is a gene therapy company, which is focused on developing treatments and platform technologies. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. It is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. It has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington’s disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson’s disease, Lewy body dementia and Gaucher’s disease. It also focuses on tauopathies and indications in neuro-oncology.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan